Brainstorm Cell Therapeutics (NASDAQ:BCLI) received a $9.00 target price from analysts at Maxim Group in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target suggests a potential upside of 163.93% from the stock’s previous close.
Separately, ValuEngine cut Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 21st.
Shares of Brainstorm Cell Therapeutics (BCLI) opened at $3.41 on Thursday. Brainstorm Cell Therapeutics has a 12-month low of $2.88 and a 12-month high of $5.18.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after acquiring an additional 17,657 shares during the period. Deutsche Bank AG boosted its holdings in Brainstorm Cell Therapeutics by 330.0% in the 4th quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock worth $386,000 after buying an additional 75,664 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Brainstorm Cell Therapeutics by 396.9% in the 4th quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock worth $449,000 after buying an additional 91,495 shares during the last quarter. Finally, Clearline Capital LP acquired a new stake in Brainstorm Cell Therapeutics in the 4th quarter worth about $208,000. Hedge funds and other institutional investors own 9.72% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Brainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim Group” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3252855/brainstorm-cell-therapeutics-bcli-pt-set-at-9-00-by-maxim-group.html.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.